EyePoint Pharmaceuticals Inc

(a)

Nancy S. Lurker Separation Agreement

On July 10, 2024 (the “Lurker Expiration Date”), Nancy S. Lurker’s term as Executive Vice Chair of the Company expired in accordance with the terms of that certain Employment Letter Agreement between the Company and Ms. Lurker, initially dated September 15, 2016 and subsequently amended on January 3, 2023 and July 10, 2023 (as amended, the “Lurker Employment Agreement”). Ms. Lurker continues to serve as a member and Vice Chair of the Board of Directors of the Company. On August 6, 2024, Ms. Lurker and the Company entered into a severance agreement and general release (the “Separation Agreement”), which will become effective as of August 14, 2024, the 8 thday after Ms. Lurker signed the Separation Agreement (unless earlier revoked by Ms. Lurker in accordance with the terms of the Separation Agreement). Pursuant to the Separation Agreement, subject to Ms. Lurker agreeing to a release of claims and complying with certain other continuing obligations contained therein, the Company will pay Ms. Lurker a lump sum cash payment equal to $0.3 million, less applicable taxes and withholdings. The foregoing description of the Separation Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which is filed as Exhibit 10.3 to this Form 10-Q for the quarterly period ended June 30, 2024.

In addition to the foregoing, Ms. Lurker remains eligible to participate in the Company’s annual target bonus program for fiscal year 2024 based on the target bonus percentage in the Lurker Employment Agreement. Ms. Lurker’s annual target bonus payment, if any, will be payable at the time annual performance bonuses are paid to Company management in 2025 and will be pro-rated based on the number of days during 2024 that Ms. Lurker was employed by the Company. The Company will also pay the employer portion of COBRA premiums for Ms. Lurker and her eligible dependents for the period from August 1, 2024 to January 31, 2026, except that such coverage will be discontinued if Ms. Lurker or her eligible dependents become ineligible for COBRA coverage pursuant to applicable law or insurance plan terms.

(c)

Rule 10b5-1 Trading Arrangements

The Company permits officers and directors to adopt written trading plans, known as “Rule 10b5-1 trading arrangements”, as such term defined in Item 408(a) of Regulation S-K for the purchase or sale of the Company's securities, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. During the three months ended June 30, 2024, our executive officers and directors adopted, modified orterminated Rule 10b5-1 trading arrangements for the purchase or sale of our common stock as noted below: